

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM665249

SUBMISSION TYPE:	RESUBMISSION
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL
RESUBMIT DOCUMENT ID:	900633540

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
SmithKline Beecham (Cork) Limited		07/02/2021	Corporation: UNITED KINGDOM

RECEIVING PARTY DATA

Name:	Woodward Pharma Services LLC
Street Address:	47220 Cartier Drive, Suite A
City:	Wixom
State/Country:	MICHIGAN
Postal Code:	48393
Entity Type:	Limited Liability Company: MICHIGAN

PROPERTY NUMBERS Total: 8

Property Type	Number	Word Mark
Registration Number:	2437572	1-800-AVANDIA
Registration Number:	3074190	AVANDIA
Registration Number:	2241060	AVANDIA
Registration Number:	2411346	AVANDIA
Registration Number:	2534127	AVANDIA
Registration Number:	2413102	AVANDIA
Registration Number:	2435863	AVANDIA
Registration Number:	2437571	AVANDIA.COM

CORRESPONDENCE DATA

Fax Number: 6167522500

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6167522479

Email: trademarks@wnj.com

Correspondent Name: R. Scott Keller Warner Norcross + Judd

Address Line 1: 150 Ottawa Avenue NW, Suite 1500

Address Line 4: Grand Rapids, MICHIGAN 49503

ATTORNEY DOCKET NUMBER:	185275185275
--------------------------------	--------------

NAME OF SUBMITTER:	R. Scott Keller
SIGNATURE:	/rsk/
DATE SIGNED:	08/05/2021

Total Attachments: 18

source=AVENDIA MARK ASSIGN#page1.tif
source=AVENDIA MARK ASSIGN#page2.tif
source=AVENDIA MARK ASSIGN#page3.tif
source=AVENDIA MARK ASSIGN#page4.tif
source=AVENDIA MARK ASSIGN#page5.tif
source=AVENDIA MARK ASSIGN#page6.tif
source=AVENDIA MARK ASSIGN#page7.tif
source=AVENDIA MARK ASSIGN#page8.tif
source=AVENDIA MARK ASSIGN#page9.tif
source=AVENDIA MARK ASSIGN#page10.tif
source=AVENDIA MARK ASSIGN#page11.tif
source=AVENDIA MARK ASSIGN#page12.tif
source=AVENDIA MARK ASSIGN#page13.tif
source=AVENDIA MARK ASSIGN#page14.tif
source=AVENDIA MARK ASSIGN#page15.tif
source=AVENDIA MARK ASSIGN#page16.tif
source=AVENDIA MARK ASSIGN#page17.tif
source=AVENDIA MARK ASSIGN#page18.tif

TRADEMARK AND DOMAIN NAME ASSIGNMENT

This TRADEMARK AND DOMAIN NAME ASSIGNMENT (this “**Assignment**”), dated July 2, 2021, (the “**Effective Date**”), is between (i) **GLAXO GROUP LIMITED**, a company registered in England, with registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS England (“**GGL**”), **GLAXOSMITHKLINE LLC**, a Delaware limited liability company, with registered office located at 251 Little Falls Drive, Corporation Service Company, Wilmington, DE 19808, United States (“**GSK**”), **SMITHKLINE BEECHAM LIMITED**, a company registered in England, with registered office located at 980 Great West Road, Brentford, Middlesex, TW8 9GS England (“**SKB**”), and **SMITHKLINE BEECHAM (CORK) LIMITED**, a company organized under the laws of the Republic of Ireland with registered offices located at 12 Riverwalk, Citywest Business Campus, Dublin 24 Ireland (“**SKB (Cork)**”), and together with GGL, GSK and SKB, collectively referred to herein as the “**Assignor**”) and (ii) **WOODWARD PHARMA SERVICES LLC**, a Michigan limited liability company, with a place of business at 47220 Cartier Dr., Suite A, Wixom, Michigan 48393 (the “**Assignee**” and, collectively with the Assignor, the “**Parties**”).

A. Assignee, GSK, SKB (Cork) and GlaxoSmithKline Trading Services Limited (registered number 406446), a company organized and existing under the laws of Ireland, having its registered office at 12 Riverwalk, Citywest Business Campus, Citywest, Dublin 24, Ireland, and having a UK principal place of business at 980 Great West Road, Brentford, Middlesex TW8 9GS, UK are party to an Asset Purchase Agreement, dated June 30, 2021 (as may be amended, restated or otherwise modified from time to time, the “**Purchase Agreement**”).

B. Under the Purchase Agreement, and subject to the terms thereof, the Assignor sold to the Assignee all of the Assignor’s rights, title, and interest in and to each Trademark and Internet domain name that is a Purchased Asset (each such Trademark, an “**Assigned Trademark**” and each such Internet domain name, an “**Assigned Domain Name**”, collectively, the “**Assigned Assets**”), including those Assigned Assets set forth in **Schedule A** and including all rights under common law relating to each Assigned Trademark, the corresponding registrations and applications for each Assigned Trademark, and the goodwill appurtenant to each of the foregoing.

The Parties hereby agree as follows:

- 1. Assignment.** The Assignor hereby assigns, transfers, delivers, and conveys to the Assignee, and the Assignee hereby purchases and acquires from the Assignor, all of the Assignor’s right, title, and interest in and to (a) each Assigned Trademark, including all rights under common law relating to each Assigned Trademark, the corresponding registrations in the U.S. Patent and Trademark Office for each Assigned Trademark (including any renewals and extensions of such registrations, now or hereafter in effect), and the goodwill appurtenant to each of the foregoing described in this clause (a); (b) each Assigned Domain Name (including any renewals of such registrations, now or hereafter in effect) and the goodwill appurtenant to each of the foregoing described in this clause (b); and (c) all rights to bring, make, oppose, defend, appeal proceedings, claims or actions, whether at law or in equity, for infringement, dilution, or misuse of each Assigned Asset against any Person, and all rights against any Person to recover damages, to recover profits,

and to secure injunctive relief for all past, present, or future infringement, dilution, or misuse of each Assigned Asset, in each case, other than the Retained Rights.

2. **Forfeiture of Domain Names.** If, at any point, that certain Trademark License Agreement, dated as of the date hereof, by and among GSK, SKB, SKB (Cork) and Assignee is terminated for any reason, then any and all right, title, and interest in and to each of those Assigned Domain Names identified in **Schedule B** (the “**Subject Domain Names**”) shall automatically be assigned back to the applicable Assignor thereof or to an Affiliate or other successor designated by Assignor, and the Parties shall cooperate to execute such documentation as may be reasonably requested by the Assignor to evidence such assignment as promptly as practicable following the effective date of such termination.
3. **Purchase Agreement Controls.** The terms hereof are subject in all respects to the terms of the Purchase Agreement, which is hereby incorporated herein by reference. Nothing herein in any way supersedes, enlarges, narrows, or modifies (and nothing herein will be deemed to supersede, enlarge, narrow, or modify) any provision of the Purchase Agreement, except as otherwise expressly set forth herein. If there is any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, then the terms of the Purchase Agreement will control.
4. **Further Assurances.**
 - (a) Each Party hereto agrees to cooperate fully with the other Party to carry into effect the intents and purposes of this Assignment in accordance with the terms of the Purchase Agreement. Each Party agrees to undertake, at the Assignee’s expense (solely with respect to any third party fees), all such reasonable acts and/or execute or procure the execution of all documents as may be reasonably required by law or reasonably necessary to vest each Assigned Asset in the Assignee (or, solely in respect of the Subject Domain Names and to the extent provided in Section 2 to, the applicable Assignor) or otherwise perfect the legal and beneficial title of the Assignee (or, solely in respect of the Subject Domain Names and to the extent provided in Section 2 to, the applicable Assignor) in and to the Assigned Assets, including, with respect to the Assigned Domain Names, and without limitation: (a) unlocking the domain with the applicable registrar, (b) obtaining an authorization code for the transfer of the Assigned Domain Name from the applicable registrar, and (c) notifying Assignee of the completion of part (a) and (b) and providing such authorization code to Assignee (“**Initiation Notification**”). Assignee shall promptly complete the transfer upon its receipt of the Initiation Notification.
 - (b) Notwithstanding the foregoing paragraph or any provision of the Purchase Agreement, if a period of twelve (12) months passes from the Effective Date and the recordal of the assignment of any Assigned Asset has not been initiated by the Assignee, and the Assigned Trademarks and/or Assigned Domain Names remain in the name of the Assignor in the records of the relevant trademark registry or

domain name registrar, the Assignor shall have no obligation to renew, maintain, or pay any fees in connection with such Assigned Trademark or Assigned Domain Name; provided, that the Assignor shall have no obligation to renew, refile, maintain, pay any fees or take other action from and after the date hereof with respect to any Assigned Trademark or Assigned Domain Name not in use by the Assignor or its Affiliates as of the date hereof.

- (c) Assignor hereby covenants and agrees that neither Assignor nor any of its Affiliates shall make any commercial use of the Internet domain name “Avodart.com” (the “**Restricted Domain Name**”) in connection with the marketing and Distribution of Products within the Territory; provided, that for the avoidance of doubt, the Restricted Domain Name shall not constitute an Assigned Domain Name for any purpose hereunder and Assignor and its Affiliates shall retain all rights, title and interest in and to the Restricted Domain Name.
- (d) If at any time Assignor and its Affiliates shall have made a final determination to discontinue the marketing and Distribution of Avodart outside of the Territory (other than in connection with a transaction contemplated by Section 4(e) but subject to the terms thereof) and shall have made a final determination to cease use of the Restricted Domain Name, Assignor will notify Assignee of such decision in writing (such notice, the “**Avodart.com Notice**”), which Avodart.com Notice shall specify the purchase price for and other terms upon which Assignor and its Affiliates would be willing to sell, assign, transfer, deliver and convey to the Assignee or one of its Affiliates all of Assignor’s and its Affiliates’ right, title and interest in and to the Restricted Domain Name. Within a period of thirty (30) days following Assignee’s receipt of the Avodart.com Notice, Assignee or one of its Affiliates may deliver to Assignor written notice (an “**Acceptance Notice**”) that Assignee or such Affiliate of Assignee elects to enter into an agreement with Assignor or its applicable Affiliate(s) on the terms and conditions described in the Avodart.com Notice and such other terms as may be agreed between the parties in a definitive agreement with respect to the transactions contemplated by the Avodart.com Notice (a “**Definitive Agreement**”). If Assignee or such Affiliate so elects, then Assignor or its applicable Affiliate(s) will negotiate with Assignee in good faith to enter into an agreement with Assignee or its applicable Affiliate(s) on the terms and conditions set forth in the Avodart.com Notice. If Assignee does not deliver an Acceptance Notice within such time period or does not enter into a Definitive Agreement with Assignor or its applicable Affiliate(s) within sixty (60) days of delivering the Acceptance Notice, then Assignor and its Affiliates shall have no further restriction or obligation to Assignee or its Affiliates concerning the transactions contemplated by the Avodart.com Notice.
- (e) Nothing herein shall restrict Assignor from transferring, selling, licensing or assigning to any Third Party any right, title or interest in, to or under the Restricted Domain Name; provided, that the transferee, licensee or assignee, as applicable, of

such transfer, sale, license or assignment assumes in writing, at the time of the closing of such transfer, sale, license or assignment, the obligations of Assignor under Section 4(c) and Section 4(d).

5. Miscellaneous.

(a) Amendments; Waivers.

- (i) This Assignment can be amended if, and only if, such amendment is in writing and is signed by each Party.
- (ii) No waiver by any Party of such Party's rights, powers, or privileges hereunder, will be binding against the other Party. No such waiver by a Party will be enforceable against such Party unless such waiver was given in a written instrument signed by such Party. The waiver by any Party of any of such Party's rights, powers, or privileges hereunder arising because of any claimed breach, default, or misrepresentation under or with respect to a provision hereof, whether intentional or not, will not thereby extend (and will not be deemed to thereby extend) to any prior separate or subsequent breach, default, or misrepresentation, respectively, by such Party and will not affect in any way any rights, powers, or privileges arising by virtue of any such prior separate or subsequent occurrence. No failure or delay by any Party in exercising any of such Party's rights, powers, or privileges hereunder will operate as a waiver thereof, nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power, or privilege hereunder or otherwise.
- (iii) Emails, including emails that bear an electronic "signature block" identifying the sender, do not constitute signed writings for purposes of this Section 5(a).

(b) Governing Law. This Assignment is governed by, and is to be interpreted and enforced in accordance with, the internal Laws of the State of Delaware without giving effect to any choice of law or conflict of laws rules or provisions (whether of the State of Delaware or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Delaware.

(c) Counterparts. Each Party is permitted to execute this Assignment in multiple counterparts, each of which will be deemed an original and all of which taken together will constitute one and the same instrument.

(d) Third-party Beneficiaries. No provision hereof is intended to confer, no provision hereof will confer, and no provision hereof will be deemed to confer benefits,

rights, or remedies upon any Person other than upon the Parties, their respective successors, and their respective permitted assigns.

- (e) **Entire Agreement.** This Assignment (i) is a final, complete, and exclusive statement of the agreement and understanding of the Parties with respect of the subject matter hereof, (ii) constitutes the entire agreement of the Parties with respect to the subject matter hereof, and (iii) supersedes, merges, and integrates herein any prior and contemporaneous negotiations, discussions, representations, understandings, and agreements between any of the Parties, whether oral or written, with respect to the subject matter hereof.
- (f) **Captions.** Titles, captions, and headings included herein are for convenience of reference only and are not to affect the meaning, construction, or interpretation hereof or of any provision hereof.
- (g) **Severability.** If any portion or provision hereof is to any extent determined to be illegal, invalid, or unenforceable by a court of competent jurisdiction, then the remainder hereof, and the application of such portion or provision in circumstances other than those as to which it is so determined to be illegal, invalid, or unenforceable, as applicable, will not be affected thereby. Without limiting the generality of the immediately foregoing sentence, if any portion or provision hereof is determined by any court of competent jurisdiction to be unenforceable by reason of excessive scope as to geographic, temporal, or functional coverage, then such provision will be deemed to extend only over the maximum geographic, temporal, and functional scope as to which such court determines it is permitted to be enforceable.
- (h) **Interpretation; Construction.**
 - (i) Capitalized terms used but not otherwise defined herein shall have the meanings ascribed to them in the Purchase Agreement.
 - (ii) Unless otherwise expressly provided herein, any reference to a contract (including this Assignment) and all other contractual instruments is a reference to such contract or instrument (including all exhibits, schedules, annexes, indices, appendices, and other attachments thereto) as the same might be amended or otherwise modified in accordance with the terms thereof.
 - (iii) The Parties have participated jointly in the negotiation and drafting hereof, and any rule of construction or interpretation otherwise requiring this Assignment to be construed or interpreted against any Party by virtue of the authorship hereof is not to affect the construction and interpretation hereof.

- (i) **Adequate Consideration.** Each Party acknowledges that such Party has received adequate consideration to support such Party's entry into this Assignment and the promises made by such Party hereunder.

[Signature Page Follows]

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: Asell.
Name:
Title: John Sadler, Authorised signatory for and on behalf of The Wellcome Foundation Limited, Corporate Director of G

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:

SMITHKLINE BEECHAM LIMITED

By: Asell.
Name:
Title: John Sadler, Authorised signatory for and on behalf of Edinburgh Pharmaceutical Industries Limited

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____
Name:
Title:

WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: *Hatixhe Hoxha*
Name: **Hatixhe Hoxha**
Title: **Assistant Secretary**

SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____
Name:
Title:


WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

[Signature Page to Trademark and Domain Name Assignment]

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.


GLAXO GROUP LIMITED

By: 
Name:
Title: John Sadler, Authorised signatory for and on behalf of The Wellcome Foundation Limited, Corporate Director

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:

SMITHKLINE BEECHAM LIMITED

By: 
Name:
Title: John Sadler, Authorised signatory for and on behalf of Edinburgh Pharmaceutical Industries Limited

SMITHKLINE BEECHAM (CORK) LIMITED

By: _____
Name:
Title:

WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:

SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: Giuseppe Whelan Electronically signed
by: Giuseppe Whelan
Reason: I am signing
for the reasons as
stated in the document.
Date: Jun 29, 2021
13:12 GMT+1
Name: Giuseppe Whelan
Title: Director of SmithKline Beecham (Cork) Limited

WOODWARD PHARMA SERVICES LLC

By: _____
Name: David Risk
Title: Authorized Signatory

IN WITNESS WHEREOF this Assignment has been executed the day and year appearing above.

GLAXO GROUP LIMITED

By: _____
Name:
Title:

GLAXOSMITHKLINE LLC

By: _____
Name:
Title:


SMITHKLINE BEECHAM LIMITED

By: _____
Name:
Title:

**SMITHKLINE BEECHAM (CORK)
LIMITED**

By: _____
Name:
Title:

WOODWARD PHARMA SERVICES LLC

By:  _____
Name: David Risk
Title: Authorized Signatory

Schedule A
Assigned Trademarks

Trademark	U.S. Registration No.	Registration Date	Assignor Party
1-800-AVANDIA	2437572	20 Mar 2001	SmithKline Beecham (Cork) Limited
AVANDIA	3074190	28 Mar 2006	SmithKline Beecham (Cork) Limited
AVANDIA	2241060	20 Apr 1999	SmithKline Beecham (Cork) Limited
AVANDIA (STYLIZED) 	2411346	5 Dec 2000	SmithKline Beecham (Cork) Limited
AVANDIA (STYLIZED) 	2534127	29 Jan 2002	SmithKline Beecham (Cork) Limited
AVANDIA (STYLIZED) 	2413102	12 Dec 2000	SmithKline Beecham (Cork) Limited
AVANDIA (stylized) (in color) (teal/red) 	2435863	13 Mar 2001	SmithKline Beecham (Cork) Limited
AVANDIA.COM	2437571	20 Mar 2001	SmithKline Beecham (Cork) Limited
JALYN	4003717	26 Jul 2011	Glaxo Group Limited

Assigned Domain Names

Domain Name	Registration Date	Assignor Party
avandia.com	29 May 1998	SmithKline Beecham (Cork) Limited
avandia.us	19 Apr 2002	SmithKline Beecham (Cork) Limited
avandiaaccess.com	26 Feb 2009	SmithKline Beecham (Cork) Limited

AvandiaAdvantage.com	31 Aug 2006	SmithKline Beecham (Cork) Limited
AvandiaAlerts.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Alerts.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaandYou.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaBackground.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-ClassAction.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-ClassActionLawsuit.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaClassActionLawsuits.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-ClassActionLawsuits.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaClinicalTrials.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-ClinicalTrials.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaClinicalTrialsRegister.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-ClinicalTrialsRegister.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaConcern.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaConcerns.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaDetails.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandiadiabetescare.com	20 Oct 2006	SmithKline Beecham (Cork) Limited
avandia-diabetescare.com	20 Oct 2006	SmithKline Beecham (Cork) Limited
avandiadiabetescareprogram.com	20 Oct 2006	SmithKline Beecham (Cork) Limited
avandia-diabetescareprogram.com	20 Oct 2006	SmithKline Beecham (Cork) Limited
avandiadirect.com	30 Oct 2003	Glaxo Group Limited
Avandia-Direct.com	08 Dec 2003	Glaxo Group Limited
avandiafact.com	12 Jun 2007	SmithKline Beecham (Cork) Limited
avandia-fact.com	12 Jun 2007	SmithKline Beecham (Cork) Limited

avandia-facts.com	12 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaGetTheDetails.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandiahcp.com	13 Nov 2008	SmithKline Beecham (Cork) Limited
AvandiaHealthcareProfessional.com	10 Nov 2008	SmithKline Beecham (Cork) Limited
Avandia-HealthcareProfessional.com	10 Nov 2008	SmithKline Beecham (Cork) Limited
AvandiaHealthcareProfessionals.com	10 Nov 2008	SmithKline Beecham (Cork) Limited
AvandiaHeartAttackRisk.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-HeartAttackRisk.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
avandiaican.com	29 Aug 2007	SmithKline Beecham (Cork) Limited
avandia-ican.com	18 Apr 2006	SmithKline Beecham (Cork) Limited
AvandiaImportantSafetyInformation.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaISI.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandia-joinican.com	18 May 2006	Glaxo Group Limited
AvandiaLitigationNews.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandiamd.com	29 Aug 2007	SmithKline Beecham (Cork) Limited
avandiamedicinesaccess.com	08 Nov 2010	SmithKline Beecham (Cork) Limited
AvandiamedicinesREMS.com	03 Feb 2011	SmithKline Beecham (Cork) Limited
AvandiaNYou.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandiapride.com	23 Sep 2005	Glaxo Group Limited
avandia-professional.com	13 Nov 2008	SmithKline Beecham (Cork) Limited
avandiaprogram.com	02 Feb 2007	SmithKline Beecham (Cork) Limited
avandia-program.com	02 Feb 2007	SmithKline Beecham (Cork) Limited
AvandiaQandA.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaQnA.com	28 Jun 2007	SmithKline Beecham (Cork) Limited

AvandiaQuestion.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaQuestions.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaQuestionsAndAnswers.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaRecalls.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Recalls.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Risk.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
avandia-rosiglitazone.com	11 Apr 2012	SmithKline Beecham (Cork) Limited
AvandiaRosiglitazoneMedicinesAccessprogram.com	03 Feb 2011	SmithKline Beecham (Cork) Limited
AvandiaSafety.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Safety.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyAlert.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyAlert.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyAlerts.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyAlerts.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyConcern.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyConcern.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyConcerns.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyConcerns.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyInformation.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyInformation.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaSafetyProfile.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SafetyProfile.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
avandiasavings.com	29 Aug 2007	SmithKline Beecham (Cork) Limited

AvandiaSideEffect.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-SideEffect.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
avandiaspeakersedge.com	01 Sep 2009	SmithKline Beecham (Cork) Limited
avandiastraighttalk.com	19 Jul 2007	SmithKline Beecham (Cork) Limited
avandiasweepstakes.com	24 Oct 2003	Glaxo Group Limited
AvandiaWarnings.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Warnings.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
AvandiaWithdrawal.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Avandia-Withdrawal.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
buyavandia.com	31 Aug 2006	SmithKline Beecham (Cork) Limited
Factsaboutavandia.com	05 May 2010	SmithKline Beecham Limited
joinavandia.com	29 Aug 2007	SmithKline Beecham (Cork) Limited
join-avandia.com	07 Jun 2006	SmithKline Beecham (Cork) Limited
MyAvandia.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
SafetyofAvandia.com	27 Jun 2007	SmithKline Beecham (Cork) Limited
Thefactsaboutavandia.com	05 May 2010	SmithKline Beecham Limited
WhyAvandia.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
WhyDidYourDoctorPrescribeAvandia.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
WithAvandia.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
YourAvandia.com	28 Jun 2007	SmithKline Beecham (Cork) Limited
4jalyn.com	15 Jun 2010	Glaxo Group Limited
Aboutjalyn.com	15 Jun 2010	Glaxo Group Limited
jalyn.com	03 Jan 1995	Glaxo Group Limited
jalyn.org	15 Jun 2010	Glaxo Group Limited
Jalyndrug.com	15 Jun 2010	Glaxo Group Limited
Jalynfacts.com	15 Jun 2010	Glaxo Group Limited

Jalynforme.com	15 Jun 2010	Glaxo Group Limited
Jalyninfo.com	15 Jun 2010	Glaxo Group Limited
Jalyntoday.com	15 Jun 2010	Glaxo Group Limited
Yourjalyn.com	15 Jun 2010	Glaxo Group Limited
Coreg.com	13 Sep 2000	SmithKline Beecham Limited
CoregCR.com	26 Oct 2005	SmithKline Beecham Limited
Goavodart.com	31 Jul 2007	SmithKline Beecham Limited

Schedule B
Subject Domain Names

Domain Name	Registration Date	Assignor Party
Coreg.com	13 Sep 2000	SmithKline Beecham Limited
CoregCR.com	26 Oct 2005	SmithKline Beecham Limited
Goavodart.com	31 Jul 2007	SmithKline Beecham Limited